Cryopreserved cells facilitate cell-based drug discovery

Drug Discovery Today

Volumn 12, Issue 13-14, 2007, Pages 521-526

  Zaman, Guido J R ^a   de Roos, Jeroen A D M ^a   Blomenröhr, Marion ^a   van Koppen, Chris J ^a   Oosterom, Julia ^a  

^a Organon BioSciences   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHEMOKINE RECEPTOR ANTAGONIST; CINACALCET; CYCLIC AMP; FOLLITROPIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; ION CHANNEL; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; MITOMYCIN C; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE; REAGENT; REPERTAXIN; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

BIOCHEMISTRY; CALCIUM TRANSPORT; CARCINOMA; CELL CRYOPRESERVATION; CELL CULTURE; CELL FUNCTION; CELL STRAIN HEK293; CHEMOLUMINESCENCE; CHO CELL; CRYOPRESERVATION; CYTOLYSIS; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PULSE THERAPY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; FLUORESCENCE; GENETIC TRANSFECTION; HUMAN; HYPERPARATHYROIDISM; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LIGAND BINDING; MITOSIS INHIBITION; NONHUMAN; REPERFUSION INJURY; REPORTER GENE; REVIEW; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL ASSAY; CELL LINE; CRYOPRESERVATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED;

EID: 34447268009     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.05.008     Document Type: Review

References (44)

1. Fox, et al. High-throughput screening: Update on practices and success. J. Biomol. Screen. 11 (2006) 864-869
2. Overington J.P., et al. How many drug targets are there?. Drug Discov. Today 5 (2006) 993-996
3. Fox S., et al. High-throughput screening: Searching for higher productivity. J. Biomol. Screen. 9 (2004) 354-358
4. Eglen R.M. Functional G protein-coupled receptor assays for primary and secondary screening. Comb. Chem. HTS 8 (2005) 311-318
5. Williams C. cAMP detection methods in HTS: Selecting the best from the rest. Nat. Rev. Drug Discov. 3 (2004) 125-135
6. Gabriel D., et al. High throughput screening technologies for direct cyclic AMP measurement. Assay Drug Dev. Technol. 1 (2003) 291-303
7. Chambers C., et al. Measuring intracellular calcium fluxes in high throughput mode. Comb. Chem. & HTS 6 (2003) 355-362
8. Le Poul E., et al. Adaptation of Aequorin functional assay to high throughput screening. J. Biomol. Screen. 7 (2002) 57-65
9. Zlokarnik G., et al. Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science 279 (1998) 84-88
10. Cacace A., et al. An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors. Drug Discov. Today 8 (2003) 785-792
11. Kunapuli P., et al. Development of an intact cell reporter gene β-lactamase assay for G protein-coupled receptors for high-throughput screening. Anal. Biochem. 314 (2003) 16-29
12. Oosterom J., et al. High-throughput screening using β-lactamase reporter-gene technology for identification of low-molecular weight antagonists of the human gonadotropin releasing hormone receptor. Assay Drug Dev. Technol. 3 (2005) 143-154
13. Oakley R.H., et al. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay Drug Dev. Technol. 1 (2002) 21-30
14. Grånäs C., et al. High content screening for G protein-coupled receptors using cell-based translocation assays. Comb. Chem. HTS 8 (2005) 301-309
15. Xu J., et al. Ion-channel assay technologies: quo vadis?. Drug Discov. Today 6 (2001) 1278-1287
16. González J.E., et al. Cell-based assays and instrumentation for screening ion-channel targets. Drug Discov. Today 4 (1999) 431-439
17. Zaman G.J.R., et al. Fluorescence assays for high-throughput screening of protein kinases. Comb. Chem. HTS 6 (2003) 313-320
18. von Ahsen O., and Bömer U. High-throughput screening for kinase inhibitors. Chem. Bio. Chem. 6 (2005) 481-490
19. Zaman G.J.R., et al. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem. Pharmacol. 57 (1999) 57-64
20. Minor, et al. Assays to measure the activation of membrane tyrosine kinase receptors: Focus on cellular methods. Curr. Opin. Drug Discov. Dev. 6 (2003) 760-765
21. Williams C., and Sewing A. G-protein coupled receptor assays: To measure affinity or efficacy that is the question. Comb. Chem. HTS 8 (2005) 285-292
22. Soudijn W., et al. Allosteric modulation of G protein-coupled receptors; perspectives and recent developments. Drug Discov. Today 9 (2004) 752-758
23. Nemeth E., et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4040-4045
24. Bertini R., et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11791-11796
25. van Straten N.C.R., et al. The first orally active low molecular weight agonists for the LH receptor: Thienopyr(im)idines with therapeutic potential for ovulation induction. Chem. Bio. Chem. 3 (2002) 1023-1026
26. van Straten N.C.R., et al. Identification of substituted 6-amino-4-phenylhydroquinoline derivatives: Potent antagonists for the follicle-stimulating hormone receptor. J. Med. Chem. 48 (2005) 1697-1700
27. Jäschke, et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J. Biol. Chem. 281 (2006) 9841-9844
28. In: Hüser J. (Ed). High Throughput-Screening in Drug Discovery (2006), Wiley-VCH
29. Kostenis E., et al. Techniques: Promiscuous Gα proteins in basic research and drug discovery. Trends Pharmacol. Sci. 26 (2005) 595-602
30. Weetall M., et al. A homogenous fluorometric assay for measuring cell adhesion to immobilized ligand using V-well plates. Anal. Biochem. 293 (2001) 277-287
31. Zuck P., et al. A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Anal. Biochem. 334 (2004) 344-355
32. Digan M.E., et al. Evaluation of division-arrested cells for cell-based high-throughput screening and profiling. J. Biomol. Screen. 10 (2005) 615-623
33. Fursov N., et al. Improving consistency of cell-based assays by using division-arrested cells. Assay Drug Dev. Technol. 3 (2005) 7-15
34. Kunapuli P., et al. Application of division arrest technology to cell-based HTS: Comparison with frozen and fresh cells. Assay Drug Dev. Technol. 3 (2005) 17-26
35. Verweij J., and Pinedo H.M. Mitomycin C: mechanism of action, usefulness and limitations. Anti-Cancer Drugs 1 (1990) 5-13
36. Glaser V. An interview with Thomas Livelli. Assay Drug Dev. Technol. 3 (2005) 1-6
37. Vasudevan C., et al. Improving high-content-screening assay performance by using division-arrested cells. Assay Drug Dev. Technol. 3 (2005) 515-523
38. + efflux assay. Assay Drug Dev. Technol. 4 (2006) 83-88
39. Zhu Z., et al. Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. J. Biomol. Screen. 12 (2007) 248-254
40. ® transcriptional assay for high-throughput screening of G-protein-coupled receptors. J. Biomol. Screen. 11 (2006) 644-651
41. McMillan K., et al. Allosteric inhibitors of inducible nitric oxide synthase discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1506-1511
42. Heydorn A., et al. Protein translocation assays: key tools for accessing new biological information with high-throughput microscopy. Methods Enzymol. 414 (2006) 513-530
43. Zaman G.J.R., et al. Cell-based screening. Drug Discov. Today 9 (2004) 828-830
44. Gebhardt R., et al. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 35 (2003) 145-213